Oral Paclitaxel Chemotherapy Shows a Survival Difference in Metastatic Breast Cancer

San Antonio Breast Cancer Symposiumheard phase III results presented by Umanzor and colleagues: oral paclitaxel in metastatic (stage 4) breast cancer produced better response and survival than intravenous paclitaxel with less treatment-related neuropathy . Researchers evaluated oral paclitaxel combined with a p-glycoprotein pump inhibitor enabling intestinal absorption, ensequidar .
- Related topic: What is oral chemotherapy - a targeted pill? Advantages and disadvantages?
Oral chemotherapy as pills/capsules is important, especially where regular clinic travel is difficult. It also maintains stable blood concentrations and often has milder adverse effects.
Study Details
The trial included metastatic breast cancer in 402 patients, randomized 2 to 1. Experimental treatment was weekly 3 days of 205 mg / m² oral paclitaxel plus ensequidar; controls received every 3 weeks intravenous 175 mg / m² paclitaxel.
Primary endpoint was tumor response confirmed radiologically at two consecutive timepoints; secondary endpoints were progression-free and overall survival.
Results
- Objective response was % 35.8 with oral paclitaxel / ensequidar versus % 23.4 intravenously.
- Ongoing progression-free survival analysis, duration of disease control, showed medians of 9.3 and 8.3 months respectively.
- Median overall survival was 27.9 months orally versus 16.9 intravenously.
- Adverse Effects: The oral group reported more neutropenia, infection, and gastrointestinal effects. Neuropathy, nerve damage in distal hands and feet, was overall lower in the intravenous group (% 17 versus % 57), while severe grade 3 symptoms occurred in % 1 of oral versus % 8 of intravenous patients.
This oral form offers an option, especially when travel is difficult, though blood counts still need monitoring.
Durable responses, less neuropathy, and substantial survival benefit make the findings promising and potentially practice-changing.
Dr. Umanzor said the next step tests tolerability in patients at high peripheral neuropathy risk. Monotherapy or combinations could also be studied in other cancers.
He noted that despite blinded assessment of the confirmed response endpoint, clinical treatment was not blinded, potentially biasing adverse event reports. Statistical power covered confirmed response only, not secondary endpoints.
Sources
Oral paclitaxel with encequidar: The first orally administered paclitaxel shown to be superior to IV paclitaxel on confirmed response and survival with less neuropathy: A phase III clinical study in metastatic breast cancer.
SABCS 2019, GS6-01.
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.